abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

このページは 日本語 では利用できません。English で表示されています

記事

2005年3月30日

著者:
UK Department for International Development (DFID)

Renewed Commitment to Government – Industry Partnership to Improve Access to Medicines

The UK Government and the world’s largest pharmaceutical companies today committed to continue to work together to help increase access to essential medicines for the world’s poorest countries...The UK Government’s framework for good practice has been developed with the support and input of the pharmaceutical industry, including GlaxoSmithKline (GSK), AstraZeneca, Merck & Co., Inc., Pfizer, the Association of the British Pharmaceutical Industry (ABPI) and the American Pharmaceutical Group (APG)...[which] represents eleven US pharmaceutical companies, including Abbott Laboratories, Amgen, Bristol-Myers Squibb, Chiron Vaccines, Janssen-Cilag Ltd [part of Johnson & Johnson], Lilly [Eli Lilly], Merck Sharp & Dohme, Pfizer, Procter & Gamble Pharmaceuticals, Schering-Plough and Wyeth Pharmaceuticals.